Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT04644770 trial: what clinicians have said so far
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
- NCT04644770 ↗
- Active, not recruiting
- Janssen Research & Development, LLC
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT04644770 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04644770 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Prostatic Neoplasms; Adenocarcinoma
- Interventions
- JNJ-69086420; JNJ-78278343; Stereotactic body radiation therapy
- Arms
- Part 1: Dose Escalation · Experimental
- Part 2: Dose Expansion · Experimental
- Part 3: Combination Therapy · Experimental
- Part 4: HSPC Expansion · Experimental
- Enrollment
- 144
- Primary outcomes
- Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
- Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
- Number of Participants with AEs by Severity
- Sponsor
- Janssen Research & Development, LLC
- Start
- Nov 12, 2020
- Primary completion
- Dec 8, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04644770 · updated Nov 3, 2026
Publications
linked from the registry- Lehner F, Salemi S, Millan C, Kundig C, Eberli D. Inhibition of Growth and Induction of Apoptosis of Human Prostate Cancer Cells by Enzymatic Blockage of Kallikreins. Prostate Cancer. 2026 Jan 11;2026:7871208. doi: 10.1155/proc/7871208. eCollection 2026. PubMed 41531507